Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Open accessThe DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Abstract
Nearly 350 IgG-based therapeutics are approved for clinical use or are under development for many diseases lacking adequate treatment options. These include molecularly engineered biologicals comprising the IgG Fc-domain fused to various effector molecules (so-called Fc-fusion proteins) that confer the advantages of IgG, including binding to the neonatal Fc receptor (FcRn) to facilitate in vivo stability, and the therapeutic benefit of the specific effector functions. Advances in IgG structure-function relationships and an understanding of FcRn biology have provided therapeutic opportunities for previously unapproachable diseases. This article discusses approved Fc-fusion therapeutics, novel Fc-fusion proteins and FcRn-dependent delivery approaches in development, and how engineering of the FcRn-Fc interaction can generate longer-lasting and more effective therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Peters, T. (1985) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60065-0 · Cited by 2,181
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 2×
“Aflibercept has thus proven to exhibit markedly improved pharmacokinetics (Holash et al., 2002) and has been shown to effectively inhibit angiogenesis by acting as a decoy receptor that binds VEGF-A and VEGF-B as well as placental growth factor (Papadopoulos et al., 2012).”
BackgroundDeisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis
Lovell, D. J., Giannini, E. H., Reiff, A., Cawkwell, G. D., Silverman, E. D., Nocton, J. J., Stein, L. D., Gedalia, A., Ilowite, N. T., Wallace, C. A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003163421103 · Cited by 1,246
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Kremer, J. M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., Russell, A., Dougados, M., Emery, P., Nuamah, I. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035075 · Cited by 1,058
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Papadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., Pyles, E. A., Yancopoulos, G. D., Stahl, N., & Wiegand, S. J. (2012) · Angiogenesis · doi:10.1007/s10456-011-9249-6 · Cited by 1,037
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Post-translational modifications in the context of therapeutic proteins
Walsh, G., & Jefferis, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1252 · Cited by 1,005
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
An Fc receptor structurally related to MHC class I antigens
Simister, N. E., & Mostov, K. E. (1989) · Nature · doi:10.1038/337184a0 · Cited by 729
Larsen, C. P., Pearson, T. C., Adams, A. B., Tso, P., Shirasugi, N., Strobertb, E., Anderson, D., Cowan, S., Price, K., Naemura, J., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00749.x · Cited by 723
Junghans, R. P., & Anderson, C. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5512 · Cited by 684
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640 · cited 2×
“…wherein both hypogammaglobulinemia and hypoalbuminemia are observed along with a commensurate decrease in plasma half-life for each of these molecules (Akilesh et al., 2007; Chaudhury et al., 2003; Ghetie et al., 1996; Israel et al., 1996; Junghans & Anderson, 1996; Roopenian et al., 2003).”
BackgroundIntravenous gammaglobulin suppresses inflammation through a novel TH2 pathway
Anthony, R. M., Kobayashi, T., Wermeling, F., & Ravetch, J. V. (2011) · Nature · doi:10.1038/nature10134 · Cited by 633
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid
Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A., & Muchmore, E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2131556100 · Cited by 625
Designing CD4 immunoadhesins for AIDS therapy
Capon, D. J., Chamow, S. M., Mordenti, J., Marsters, S. A., Gregory, T., Mitsuya, H., Byrn, R. A., Lucas, C., Wurm, F. M., Groopman, J. E., et al. (1989) · Nature · doi:10.1038/337525a0 · Cited by 615
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612 · cited 2×
“, 2008), diabetes (Orban et al., 2011), lupus erythematosus (Merrill et al.”
BackgroundHoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577
Identification of a receptor required for the anti-inflammatory activity of IVIG
Anthony, R. M., Wermeling, F., Karlsson, M. C. I., & Ravetch, J. V. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810163105 · Cited by 547
Immunogenicity of protein therapeutics
De Groot, A. S., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 545
Tao, M. H., & Morrison, S. L. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.8.2595 · Cited by 530
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
Ober, R. J., Radu, C. G., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 501
Yoshida, M., Claypool, S. M., Wagner, J. S., Mizoguchi, E., Mizoguchi, A., Roopenian, D. C., Lencer, W. I., & Blumberg, R. S. (2004) · Immunity · doi:10.1016/j.immuni.2004.05.007 · Cited by 471
Self-citationAbnormally short serum half‐lives of IgG in β2‐microglobulin‐deficient mice
Ghetie, V., Hubbard, J. G., Kim, J., Tsen, M., Lee, Y., & Ward, E. S. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260327 · Cited by 469
Roopenian, D. C., Christianson, G. J., Sproule, T. J., Brown, A. C., Akilesh, S., Jung, N., Petkova, S., Avanessian, L., Choi, E. Y., Shaffer, D. J., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3528 · Cited by 456
A Theoretical Model of γ-Globulin Catabolism
BRAMBELL, F. W. R., HEMMINGS, W. A., & MORRIS, I. G. (1964) · Nature · doi:10.1038/2031352a0 · Cited by 449
Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line
Dickinson, B. L., Badizadegan, K., Wu, Z., Ahouse, J. C., Zhu, X., Simister, N. E., Blumberg, R. S., & Lencer, W. I. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6968 · Cited by 434
Self-citationCrystal structure of the complex of rat neonatal Fc receptor with Fc
Burmeister, W. P., Huber, A. H., & Bjorkman, P. J. (1994) · Nature · doi:10.1038/372379a0 · Cited by 431
Crystallographic structure studies of an IgG molecule and an Fc fragment
Huber, R., Deisenhofer, J., Colman, P. M., Matsushima, M., & Palm, W. (1976) · Nature · doi:10.1038/264415a0 · Cited by 422
Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine
Cwirla, S. E., Balasubramanian, P., Duffin, D. J., Wagstrom, C. R., Gates, C. M., Singer, S. C., Davis, A. M., Tansik, R. L., Mattheakis, L. C., Boytos, C. M., et al. (1997) · Science · doi:10.1126/science.276.5319.1696 · Cited by 403
Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life
Spiekermann, G. M., Finn, P. W., Ward, E. S., Dumont, J., Dickinson, B. L., Blumberg, R. S., & Lencer, W. I. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020400 · Cited by 402
Self-citationPotent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”
De Groot, A. S., Moise, L., McMurry, J. A., Wambre, E., Van Overtvelt, L., Moingeon, P., Scott, D. W., & Martin, W. (2008) · Blood · doi:10.1182/blood-2008-02-138073 · Cited by 392
Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex
Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391
Crystal structure of the complex of rat neonatal Fc receptor with Fc
(1995) · Trends in Genetics · doi:10.1016/0168-9525(95)90005-5 · Cited by 381
Merrill, J. T., Burgos‐Vargas, R., Westhovens, R., Chalmers, A., D'Cruz, D., Wallace, D. J., Bae, S. C., Sigal, L., Becker, J. ‐., Kelly, S., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27601 · Cited by 376
Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1651 · Cited by 372
Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences
Acqua, W. F. D., Woods, R. M., Ward, E. S., Palaszynski, S. R., Patel, N. K., Brewah, Y. A., Wu, H., Kiener, P. A., & Langermann, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5171 · Cited by 368
Lebwohl, M., Christophers, E., Langley, R., Ortonne, J. P., Roberts, J., & Griffiths, C. E. M. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.6.719 · Cited by 363
Cytokine traps: multi-component, high-affinity blockers of cytokine action
Economides, A. N., Carpenter, L. R., Rudge, J. S., Wong, V., Koehler-Stec, E. M., Hartnett, C., Pyles, E. A., Xu, X., Daly, T. J., Young, M. R., et al. (2003) · Nature Medicine · doi:10.1038/nm811 · Cited by 359
Igawa, T., Ishii, S., Tachibana, T., Maeda, A., Higuchi, Y., Shimaoka, S., Moriyama, C., Watanabe, T., Takubo, R., Doi, Y., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1691 · Cited by 353
Leach, J. L., Sedmak, D. D., Osborne, J. M., Rahill, B., Lairmore, M. D., & Anderson, C. L. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.8.3317 · Cited by 348
INTESTINAL TRANSPORT OF ANTIBODIES IN THE NEWBORN RAT
Rodewald, R. (1973) · The Journal of Cell Biology · doi:10.1083/jcb.58.1.189 · Cited by 347
Story, C. M., Mikulska, J. E., & Simister, N. E. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.6.2377 · Cited by 345
Isolation and characterization of an Fc receptor from neonatal rat small intestine
Simister, N. E., & Rees, A. R. (1985) · European Journal of Immunology · doi:10.1002/eji.1830150718 · Cited by 339
Krueger, G. G., Papp, K. A., Stough, D. B., Loven, K. H., Gulliver, W. P., & Ellis, C. N. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.127247 · Cited by 338
Crystal structure at 2.2 Å resolution of the MHC-related neonatal Fc receptor
Burmeister, W. P., Gastinel, L. N., Simister, N. E., Blum, M. L., & Bjorkman, P. J. (1994) · Nature · doi:10.1038/372336a0 · Cited by 337
Increased clearance of IgG in mice that lack β2‐microglobulin: possible protective role of FcRn
ISRAEL, E. J., WILSKER, D. F., HAYES, K. C., SCHOENFELD, D., & SIMISTER, N. E. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-775.x · Cited by 333
An IgG‐transporting Fc receptor expressed in the syncytiotrophoblast of human placenta
Simister, N. E., Story, C. M., Chen, H., & Hunt, J. S. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260718 · Cited by 332 · cited 2×
“Human FcRn was cloned in 1994 (Story et al., 1994); soon thereafter, FcRn-mediated maternofetal transport of IgG across the placenta during gestation was shown to be a key mechanism for the acquisition of passive immunity in the fetus (Leach et al., 1996; Simister et al., 1996).”
BackgroundFiran, M., Bawdon, R., Radu, C., Ober, R. J., Eaken, D., Antohe, F., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.8.993 · Cited by 330
Padler-Karavani, V., Yu, H., Cao, H., Chokhawala, H., Karp, F., Varki, N., Chen, X., & Varki, A. (2008) · Glycobiology · doi:10.1093/glycob/cwn072 · Cited by 326
Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis
Tyring, S., Gordon, K. B., Poulin, Y., Langley, R. G., Gottlieb, A. B., Dunn, M., & Jahreis, A. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.6.719 · Cited by 324
Ghaderi, D., Zhang, M., Hurtado-Ziola, N., & Varki, A. (2012) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-28-147 · Cited by 320
Raghavan, M., Bonagura, V. R., Morrison, S. L., & Bjorkman, P. J. (1995) · Biochemistry · doi:10.1021/bi00045a005 · Cited by 317
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
Ober, R. J., Martinez, C., Vaccaro, C., Zhou, J., & Ward, E. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2021 · Cited by 314
Petkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Al Khabbaz, H., Brown, A. C., Presta, L. G., Meng, Y. G., & Roopenian, D. C. (2006) · International Immunology · doi:10.1093/intimm/dxl110 · Cited by 314
Mease, P., Genovese, M. C., Gladstein, G., Kivitz, A. J., Ritchlin, C., Tak, P. P., Wollenhaupt, J., Bahary, O., Becker, J., Kelly, S., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30176 · Cited by 300
Advances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299
Dall'Era, M., Chakravarty, E., Wallace, D., Genovese, M., Weisman, M., Kavanaugh, A., Kalunian, K., Dhar, P., Vincent, E., Pena‐Rossi, C., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23047 · Cited by 294
Ephrem, A., Chamat, S., Miquel, C., Fisson, S., Mouthon, L., Caligiuri, G., Delignat, S., Elluru, S., Bayry, J., Lacroix-Desmazes, S., et al. (2008) · Blood · doi:10.1182/blood-2007-03-079947 · Cited by 292
Keystone, E. C., Schiff, M. H., Kremer, J. M., Kafka, S., Lovy, M., DeVries, T., & Burge, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20019 · Cited by 284
Ginzler, E. M., Wax, S., Rajeswaran, A., Copt, S., Hillson, J., Ramos, E., & Singer, N. G. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3738 · Cited by 284
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Receptor-mediated transport of IgG.
Rodewald, R., & Kraehenbuhl, J. P. (1984) · The Journal of cell biology · doi:10.1083/jcb.99.1.159s · Cited by 281
Dependence of antibody-mediated presentation of antigen on FcRn
Qiao, S.-W., Kobayashi, K., Johansen, F.-E., Sollid, L. M., Andersen, J. T., Milford, E., Roopenian, D. C., Lencer, W. I., & Blumberg, R. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801717105 · Cited by 280
Self-citationThe antiinflammatory activity of IgG: the intravenous IgG paradox
Nimmerjahn, F., & Ravetch, J. V. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061788 · Cited by 280
Anti‐N‐glycolylneuraminic acid antibodies identified in healthy human serum
Zhu, A., & Hurst, R. (2002) · Xenotransplantation · doi:10.1034/j.1399-3089.2002.02138.x · Cited by 273
Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates
Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300470200 · Cited by 273
Neonatal FcR Expression in Bone Marrow-Derived Cells Functions to Protect Serum IgG from Catabolism
Akilesh, S., Christianson, G. J., Roopenian, D. C., & Shaw, A. S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4580 · Cited by 269
Monoclonal Antibodies as Innovative Therapeutics
Reichert, J. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786358 · Cited by 265
pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat.
Rodewald, R. (1976) · The Journal of cell biology · doi:10.1083/jcb.71.2.666 · Cited by 264
Post-translational modifications of protein biopharmaceuticals
Walsh, G. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.06.009 · Cited by 263
Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level
Ober, R. J., Martinez, C., Lai, X., Zhou, J., & Ward, E. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402970101 · Cited by 258
West, A. P., & Bjorkman, P. J. (2000) · Biochemistry · doi:10.1021/bi000749m · Cited by 257
Genetic risk factors for inhibitors to factors VIII and IX
OLDENBURG, J., & PAVLOVA, A. (2006) · Haemophilia · doi:10.1111/j.1365-2516.2006.01361.x · Cited by 256
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
Powell, J. S., Josephson, N. C., Quon, D., Ragni, M. V., Cheng, G., Li, E., Jiang, H., Li, L., Dumont, J. A., Goyal, J., et al. (2012) · Blood · doi:10.1182/blood-2011-09-382846 · Cited by 240
Self-citationYeung, Y. A., Leabman, M. K., Marvin, J. S., Qiu, J., Adams, C. W., Lien, S., Starovasnik, M. A., & Lowman, H. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804182 · Cited by 237
Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria
Yoshida, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27821 · Cited by 237
Kessel, A., Ammuri, H., Peri, R., Pavlotzky, E. R., Blank, M., Shoenfeld, Y., & Toubi, E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5571 · Cited by 234
Bitonti, A. J., Dumont, J. A., Low, S. C., Peters, R. T., Kropp, K. E., Palombella, V. J., Stattel, J. M., Lu, Y., Tan, C. A., Song, J. J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403235101 · Cited by 233
Self-citationLi, Z., Palaniyandi, S., Zeng, R., Tuo, W., Roopenian, D. C., & Zhu, X. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012861108 · Cited by 224
Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn
Kim, J.-K., Firan, M., Radu, C. G., Kim, C.-H., Ghetie, V., & Ward, E. S. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199909)29:09<2819::aid-immu2819>3.0.co;2-6 · Cited by 222
Chamian, F., Lowes, M. A., Lin, S.-L., Lee, E., Kikuchi, T., Gilleaudeau, P., Sullivan-Whalen, M., Cardinale, I., Khatcherian, A., Novitskaya, I., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409569102 · Cited by 221
Baker, K., Qiao, S.-W., Kuo, T. T., Aveson, V. G., Platzer, B., Andersen, J.-T., Sandlie, I., Chen, Z., de Haar, C., Lencer, W. I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019037108 · Cited by 216
Self-citationEvidence to support the cellular mechanism involved in serum IgG homeostasis in humans
Ward, E. S. (2003) · International Immunology · doi:10.1093/intimm/dxg018 · Cited by 216 · cited 2×
“An important consideration to note is that these aforementioned mechanisms apply to single, monomeric IgG molecules (Baker et al., 2011, 2012; Ober et al., 2004b; Qiao et al., 2008; Ward et al., 2003, 2005).”
BackgroundMontoyo, H. P., Vaccaro, C., Hafner, M., Ober, R. J., Mueller, W., & Ward, E. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810796106 · Cited by 211 · cited 2×
“…was crossed to a Tie2-Cre expressing model, leading to a conditional deletion of FcRn in the vascular endothelium and, to a lesser extent, hematopoietic cells, Montoyo et al. (2009) were able to pinpoint the vascular endothelium as a major parenchymal cell type contributing to the IgG homeostasis.”
BackgroundPerspective – FcRn transports albumin: relevance to immunology and medicine
Anderson, C. L., Chaudhury, C., Kim, J., Bronson, C. L., Wani, M. A., & Mohanty, S. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.05.004 · Cited by 209
Kim, J., Hayton, W. L., Robinson, J. M., & Anderson, C. L. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.09.001 · Cited by 208 · cited 2×
“Furthermore, the rate of FcRn-mediated recycling has been calculated to be 42% greater than the rate of IgG production in humans, indicating that the recycling of IgG rather than its production rate is the dominant process for maintaining elevated IgG concentration in humans (Kim et al., 2007).”
BackgroundSchultze, H. E., & Heremans, J. F. (1966) · Cited by 208
Tak, P. P., Thurlings, R. M., Rossier, C., Nestorov, I., Dimic, A., Mircetic, V., Rischmueller, M., Nasonov, E., Shmidt, E., Emery, P., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23178 · Cited by 207
Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics
De Groot, A. S., & Martin, W. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.01.009 · Cited by 198
Prolonged activity of factor IX as a monomeric Fc fusion protein
Peters, R. T., Low, S. C., Kamphaus, G. D., Dumont, J. A., Amari, J. V., Lu, Q., Zarbis-Papastoitsis, G., Reidy, T. J., Merricks, E. P., Nichols, T. C., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239665 · Cited by 196
Self-citationThe three-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G
SUTTON, B. J., & PHILLIPS, D. C. (1983) · Biochemical Society Transactions · doi:10.1042/bst0110130 · Cited by 194
Ward, E. S., Martinez, C., Vaccaro, C., Zhou, J., Tang, Q., & Ober, R. J. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-08-0735 · Cited by 193
Five-Year Safety and Efficacy of Belatacept in Renal Transplantation
Vincenti, F., Blancho, G., Durrbach, A., Friend, P., Grinyo, J., Halloran, P. F., Klempnauer, J., Lang, P., Larsen, C. P., Mühlbacher, F., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009111109 · Cited by 189
Fully human antibodies from transgenic mouse and phage display platforms
Lonberg, N. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.004 · Cited by 188
Distribution of immunoglobulin G receptors in the small intestine of the young rat.
Rodewald, R. (1980) · The Journal of cell biology · doi:10.1083/jcb.85.1.18 · Cited by 186
Moreland, L., Bate, G., & Kirkpatrick, P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1989 · Cited by 177
Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1
Medesan, C., Matesoi, D., Radu, C., Ghetie, V, & Ward, E. S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.5.2211 · Cited by 175
Biological properties of a CD4 immunoadhesin
Byrn, R. A., Mordenti, J., Lucas, C., Smith, D., Marsters, S. A., Johnson, J. S., Cossum, P., Chamow, S. M., Wurm, F. M., Gregory, T., et al. (1990) · Nature · doi:10.1038/344667a0 · Cited by 174
Shapiro, A. D., Ragni, M. V., Valentino, L. A., Key, N. S., Josephson, N. C., Powell, J. S., Cheng, G., Thompson, A. R., Goyal, J., Tubridy, K. L., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367003 · Cited by 173
Self-citationWest, A. P., Herr, A. B., & Bjorkman, P. J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00113-x · Cited by 170
Datta-Mannan, A., Witcher, D. R., Tang, Y., Watkins, J., & Wroblewski, V. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607161200 · Cited by 170
Structural basis of pH-dependent antibody binding by the neonatal Fc receptor
Vaughn, D. E., & Bjorkman, P. J. (1998) · Structure · doi:10.1016/s0969-2126(98)00008-2 · Cited by 170
Tzaban, S., Massol, R. H., Yen, E., Hamman, W., Frank, S. R., Lapierre, L. A., Hansen, S. H., Goldenring, J. R., Blumberg, R. S., & Lencer, W. I. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200809122 · Cited by 169
Self-citationvan Vollenhoven, R. F., Kinnman, N., Vincent, E., Wax, S., & Bathon, J. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30372 · Cited by 167
The discovery and development of belimumab: the anti-BLyS–lupus connection
Stohl, W., & Hilbert, D. M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2076 · Cited by 166
Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
Huang, C. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.010 · Cited by 166
Wang, W., Lu, P., Fang, Y., Hamuro, L., Pittman, T., Carr, B., Hochman, J., & Prueksaritanont, T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039453 · Cited by 166
Serum albumin: recent progress in the understanding of its structure and biosynthesis.
Peters, T. (1977) · Clinical Chemistry · doi:10.1093/clinchem/23.1.5 · Cited by 163
Efficient mucosal vaccination mediated by the neonatal Fc receptor
Ye, L., Zeng, R., Bai, Y., Roopenian, D. C., & Zhu, X. (2011) · Nature Biotechnology · doi:10.1038/nbt.1742 · Cited by 159
Chapter 4 Multitasking by Exploitation of Intracellular Transport Functions
Ward, E. S., & Ober, R. J. (2009) · Advances in Immunology · doi:10.1016/s0065-2776(09)03004-1 · Cited by 156
Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
Dumont, J. A., Liu, T., Low, S. C., Zhang, X., Kamphaus, G., Sakorafas, P., Fraley, C., Drager, D., Reidy, T., McCue, J., et al. (2012) · Blood · doi:10.1182/blood-2011-08-367813 · Cited by 154
Self-citationMouse MHC class I-like Fc receptor encoded outside the MHC.
Ahouse, J. J., Hagerman, C. L., Mittal, P., Gilbert, D. J., Copeland, N. G., Jenkins, N. A., & Simister, N. E. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.11.6076 · Cited by 151
Lei, T., & Scott, D. W. (2005) · Blood · doi:10.1182/blood-2004-11-4274 · Cited by 151
Wani, M. A., Haynes, L. D., Kim, J., Bronson, C. L., Chaudhury, C., Mohanty, S., Waldmann, T. A., Robinson, J. M., & Anderson, C. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600548103 · Cited by 147
Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn
Baker, K., Qiao, S., Kuo, T. T., Kobayashi, K., Yoshida, M., Lencer, W. I., & Blumberg, R. S. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0160-9 · Cited by 145
Self-citationKim, J., Bronson, C. L., Hayton, W. L., Radmacher, M. D., Roopenian, D. C., Robinson, J. M., & Anderson, C. L. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00286.2005 · Cited by 145
Monomeric Fc Fusions: Impact on Pharmacokinetic and Biological Activity of Protein Therapeutics
Dumont, J. A., Low, S. C., Peters, R., & Bitonti, A. J. (2006) · BioDrugs · doi:10.2165/00063030-200620030-00002 · Cited by 145
Self-citationXiaobin, Z., Lapalombella, R., Joshi, T., Cheney, C. M., Gowda, A. C., Hayden-Ledbetter, M. S., Baum, P. R., Lin, T. S., Jarjoura, D. G., Lehman, A., et al. (2007) · Blood · doi:10.1182/blood-2006-12-062927 · Cited by 144
Kim, J., Tsen, M. F., Ghetie, V. F., & Ward, E. S. (1994) · European Journal of Immunology · doi:10.1002/eji.1830241025 · Cited by 144
Dore, R. K., Mathews, S. D., Schechtman, J., et al. (2007) · PubMed · Cited by 144
Abatacept for Crohn's Disease and Ulcerative Colitis
Sandborn, W. J., Colombel, J., Sands, B. E., Rutgeerts, P. J., Targan, S. R., Panaccione, R., Bressler, B. L., Geboes, K., Schreiber, S., Aranda, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.010 · Cited by 142
Koren, E., De Groot, A. S., Jawa, V., Beck, K. D., Boone, T., Rivera, D., Li, L., Mytych, D., Koscec, M., Weeraratne, D., et al. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.03.544 · Cited by 142
Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
de Vries, M. K., van der Horst-Bruinsma, I. E., Nurmohamed, M. T., Aarden, L. A., Stapel, S. O., Peters, M. J. L., van Denderen, J. C., Dijkmans, B. A. C., & Wolbink, G. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.089979 · Cited by 135
Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody
Patel, T. P., Parekh, R. B., Moellering, B. J., & Prior, C. P. (1992) · Biochemical Journal · doi:10.1042/bj2850839 · Cited by 134
Dumont, J. A., Bitonti, A. J., Clark, D., Evans, S., Pickford, M., & Newman, S. P. (2005) · Journal of Aerosol Medicine · doi:10.1089/jam.2005.18.294 · Cited by 128
Self-citationGenovese, M. C., Kinnman, N., Bourdonnaye, G. D. L., Rossi, C. P., & Tak, P. P. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30373 · Cited by 123
Vaccaro, C., Bawdon, R. E., Wanjie, S., Ober, R. J., & Ward, E. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606304103 · Cited by 120
Oral and pulmonary delivery of FSH–Fc fusion proteins via neonatal Fc receptor-mediated transcytosis
Low, S. C., Nunes, S. L., Bitonti, A. J., & Dumont, J. A. (2005) · Human Reproduction · doi:10.1093/humrep/deh896 · Cited by 120
Self-citationAbshire, T. C., Federici, A. B., Alvárez, M. T., Bowen, J. M., Carcao, M. D., Gill, J. C., Key, N. S., Kouides, P. A., Kurnik, K., Lail, A. E., et al. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02916.x · Cited by 118
What's fueling the biotech engine?
Aggarwal, S. (2007) · Nature Biotechnology · doi:10.1038/nbt1007-1097 · Cited by 118
Deng, R., Loyet, K. M., Lien, S., Iyer, S., DeForge, L. E., Theil, F., Lowman, H. B., Fielder, P. J., & Prabhu, S. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031310 · Cited by 116
Fc-Based Cytokines: Prospects for Engineering Superior Therapeutics
Jazayeri, J. A., & Carroll, G. J. (2008) · BioDrugs · doi:10.2165/00063030-200822010-00002 · Cited by 113
Chu, Q. S.-C. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802666397 · Cited by 112
Ciombor, K. K., Berlin, J. D., & Chan, E. W. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2911 · Cited by 111
Li, L., Palaniyandi, S., Zeng, R., Bai, Y., Liu, X., Wang, Y., Pauza, C. D., Roopenian, D. C., & Zhu, X. (2011) · Journal of Virology · doi:10.1128/jvi.05441-11 · Cited by 110
Waldmann, T. A., & Terry, W. D. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114947 · Cited by 107
Biosimilar, biobetter and next generation therapeutic antibodies
Beck, A. (2011) · mAbs · doi:10.4161/mabs.3.2.14785 · Cited by 106
Reichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.1.10677 · Cited by 106
Cloning and Characterization of the Bovine MHC Class I-Like Fc Receptor,
Kacskovıcs, I., Wu, Z., Simister, N. E., Frenyó, L. V., & Hammarström, L. L. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.1889 · Cited by 105
Gurbaxani, B. M., Cruz, L. L. D., Chintalacharuvu, K. R., & Morrison, S. L. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.032 · Cited by 105
Mayer, B., Zolnai, A., Frenyó, L. V., Jancsik, V., Szentirmay, Z., Hammarström, L. L. G., & Kacskovıcs, I. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01514.x · Cited by 101
Neonatal Fc Receptor Blockade by Fc Engineering Ameliorates Arthritis in a Murine Model
Patel, D. A., Cantó, A. P., Challa, D. K., Montoyo, H. P., Ober, R. J., & Ward, E. S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003780 · Cited by 99
Borys, M., Dalal, N. G., Abu‐Absi, N. R., Khattak, S. F., Jing, Y., Xing, Z., & Li, Z. J. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22644 · Cited by 97
Coleman, R. L., Duska, L., Ramirez, P. T., Heymach, J. V., Kamat, A. A., Modesitt, S. C., Schmeler, K. M., Iyer, R. B., Garcia, M. E., Miller, D. L., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70244-3 · Cited by 96
Huber, A. H., Kelley, R. F., Gastinel, L. N., & Björkman, P. J. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1220 · Cited by 92
Identification of critical IgG binding epitopes on the neonatal Fc receptor
Vaughn, D. E., Milburn, C. M., Penny, D. M., Martin, W. L., Johnson, J. L., & Björkman, P. J. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1388 · Cited by 90
Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway
Bitonti, A. J., & Dumont, J. A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.015 · Cited by 89
Self-citationStructural characterization of a human Fc fragment engineered for extended serum half-life
Oganesyan, V., Damschroder, M. M., Woods, R. M., Cook, K. E., Wu, H., & Dall’Acqua, W. F. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.01.026 · Cited by 89
Molineux, G., & Newland, A. C. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08140.x · Cited by 88
An FcRn-Dependent Role for Anti-flagellin Immunoglobulin G in Pathogenesis of Colitis in Mice
Kobayashi, K., Qiao, S., Yoshida, M., Baker, K., Lencer, W. I., & Blumberg, R. S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.059 · Cited by 88
Self-citationMagdelaine–Beuzelin, C., Vermeire, S., Goodall, M. D., Baert, F., Noman, M., Assche, G. V., Ohresser, M. C. P., Degenne, D., Dugoujon, J., Jefferis, R., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832a06bf · Cited by 88
Abrahamson, D. R., Powers, A. C., & Rodewald, R. (1979) · Science · doi:10.1126/science.493961 · Cited by 86
Sequence and expression of the FcRn in the porcine mammary gland
Schnulle, P. M., & Hurley, W. L. (2003) · Veterinary Immunology and Immunopathology · doi:10.1016/s0165-2427(02)00294-5 · Cited by 85
Antibody drug conjugates — Trojan horses in the war on cancer
Iyer, U. G., & Kadambi, V. J. (2011) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2011.07.005 · Cited by 80
Tesar, D. B., Cheung, E. J., & Björkman, P. J. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-09-0972 · Cited by 79
What's fueling the biotech engine—2010 to 2011
Aggarwal, S. (2011) · Nature Biotechnology · doi:10.1038/nbt.2060 · Cited by 79
Bai, Y., Ye, L., Tesar, D. B., Song, H., Zhao, D., Björkman, P. J., Roopenian, D. C., & Zhu, X. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115348108 · Cited by 77
Sánchez, L. M., Penny, D. M., & Björkman, P. J. (1999) · Biochemistry · doi:10.1021/bi9907330 · Cited by 69
Ying, T., Chen, W., Gong, R., Feng, Y., & Dimitrov, D. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.368647 · Cited by 68
Adamski, F. M., King, A. T., & Demmer, J. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00065-1 · Cited by 65
Zhou, J., Johnson, J. E., Ghetie, V. F., Ober, R. J., & Ward, E. S. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00952-5 · Cited by 65
Sockolosky, J. T., Tiffany, M. R., & Szoka, F. C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208857109 · Cited by 64
Haggerty, H. G., Abbott, M. A., Reilly, T. P., DeVona, D. A., Gleason, C. R., Tay, L. K., Dodge, R. W., & Aranda, R. (2007) · PubMed · Cited by 59
Suleiman, Y. B., Yoshida, M., Nishiumi, S., Tanaka, H., Mimura, T., Nobutani, K., Yamamoto, K., Takenaka, M., Aoganghua, A., Miki, I., et al. (2011) · Mucosal Immunology · doi:10.1038/mi.2011.53 · Cited by 53
Self-citationKuo, T. T., de Muinck, E. J., Claypool, S. M., Yoshida, M., Nagaishi, T., Aveson, V. G., Lencer, W. I., & Blumberg, R. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805877200 · Cited by 53
Self-citationCross-presentation of IgG-containing immune complexes
Baker, K., Räth, T., Lencer, W. I., Fiebiger, E., & Blumberg, R. S. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1100-8 · Cited by 50
Self-citationHe, Y., & Björkman, P. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106925108 · Cited by 47
Kandil, E., Egashira, M., Miyosi, O., Niikawa, N., Ishibashi, T., & Kasahara, M. (2008) · Cytogenetics and Cell Genetics · doi:10.1159/000134316 · Cited by 46
CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells
Hayden-Ledbetter, M. S., Cerveny, C., Espling, E., Brady, W., Grosmaire, L. S., Tan, P., Bader, R., Slater, S., Nilsson, C. A., Barone, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1694 · Cited by 46
Aflibercept in the Treatment of Metastatic Colorectal Cancer
Wang, T.-F., & Lockhart, A. C. (2012) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s7432 · Cited by 44
Isambert, N., Freyer, G., Zanetta, S., You, B., Fumoleau, P., Falandry, C., Favier, L., Assadourian, S., Soussan-Lazard, K., Ziti‐Ljajic, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1918 · Cited by 44
Beck, A., Wurch, T., & Corvaïa, N. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786420 · Cited by 43
Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis
Bracewell, C., Isaacs, J. D., Emery, P., & Ng, W. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903033919 · Cited by 42
Can we prevent immunogenicity of human protein drugs?
Scott, D. W., & Groot, A. S. D. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.117564 · Cited by 41
Rilonacept—CAPS and Beyond: A Scientific Journey
Stahl, N., Radin, A. R., & Mellis, S. J. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05074.x · Cited by 41
Stohl, W. (2012) · Current Rheumatology Reports · doi:10.1007/s11926-012-0254-6 · Cited by 39
Localization of the sheep FcRn in the mammary gland
Mayer, B., Zolnai, A., Frenyó, L. V., Jancsik, V., Szentirmay, Z., Hammarström, L. L. G., & Kacskovıcs, I. (2002) · Veterinary Immunology and Immunopathology · doi:10.1016/s0165-2427(02)00059-4 · Cited by 38
Sedimentation equilibrium analysis of recombinant mouse FcRn with murine IgG1
Schuck, P., Radu, C. G., & Ward, E. S. (1999) · Molecular Immunology · doi:10.1016/s0161-5890(99)00093-0 · Cited by 35
Vallée, S., Rakhe, S., Reidy, T., Walker, S., Lü, Q., Sakorafas, P., Low, S. C., & Bitonti, A. J. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0048 · Cited by 32
β2-Microglobulin Deficient Mice Catabolize IgG More Rapidly Than FcRn-α-Chain Deficient Mice
Kim, J., Bronson, C. L., Wani, M. A., Oberyszyn, T. M., Mohanty, S., Chaudhury, C., Hayton, W. L., Robinson, J. M., & Anderson, C. L. (2008) · Experimental Biology and Medicine · doi:10.3181/0710-rm-270 · Cited by 25
Mayer, L., Kaser, A., & Blumberg, R. S. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.015 · Cited by 25
Self-citationCloning and characterization of the dromedary (Camelus dromedarius) neonatal Fc receptor (drFcRn)
Kacskovıcs, I., Mayer, B., Kis, Z., Frenyó, L. V., Zhao, Y., Muyldermans, S., & Hammarström, L. L. G. (2006) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2006.02.006 · Cited by 23
Freyer, G., Isambert, N., You, B., Zanetta, S., Falandry, C., Favier, L., Trillet-Lenoir, V. N., Assadourian, S., Soussan-Lazard, K., Ziti‐Ljajic, S., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.304 · Cited by 22
Díaz-Padilla, I., Siu, L. L., Pedro-Salcedo, M. S., Razak, A. R. A., Colevas, A. D., Shepherd, F. A., Leighl, N. B., Neal, J. W., Thibault, A., Liu, L., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.319 · Cited by 14
Cited by
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Recent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Mahlangu, J., Powell, J. S., Ragni, M. V., Chowdary, P., Josephson, N. C., Pabinger, I., Hanabusa, H., Gupta, N., Kulkarni, R., Fogarty, P., et al. (2014) · Blood · doi:10.1182/blood-2013-10-529974 · Cited by 454
Self-citationPhase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Powell, J. S., Pasi, K. J., Ragni, M. V., Ozelo, M. C., Valentino, L. A., Mahlangu, J. N., Josephson, N. C., Perry, D., Manco-Johnson, M. J., Apte, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305074 · Cited by 365
Self-citationTherapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Metadata
- Authors
- Rath, T., Baker, K., Dumont, J. A., Peters, R. T., Jiang, H., Qiao, S.-W., Lencer, W. I., Pierce, G. F., & Blumberg, R. S.
- Venue
- Critical Reviews in Biotechnology
- Publisher
- Informa UK Limited
- Published
- 2013-10-24
- Volume
- 35
- Issue
- 2
- Pages
- 235-254
- ISSN
- 0738-8551 (ISSN-L)
- 1549-7801
- OpenAlex
- W2094058129
- Cited by
- 281
- References
- 201
- FWCI
- 17.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.